GLP-1 drugmaker Novo is planning another round of cuts at its U.S. headquarters in New Jersey.
In a filing with the New Jersey Department of Labor & Workforce Development, the Danish drugmaker said it expects to eliminate 215 positions at its Plainsboro base in February 2027.
A spokesperson for the company told NJBIZ, “Novo regularly evaluates its organization to ensure we are positioned to meet evolving market dynamics and patient needs. In September 2026 we announced a redesign of our U.S. sales organization to create a more streamlined commercial model while maintaining our focus on serving patients, supporting healthcare professionals, advancing our current portfolio and future pipeline and ultimately driving sustainable growth in the U.S.”
They went on, “Decisions that affect employees are never taken lightly and we are treating impacted colleagues with respect and providing appropriate support throughout the transition.”
Third round of cuts
This marks the third time that Novo will slim down its New Jersey operations as part of a restructuring initiative launched a year ago. At the time, the company said it anticipated trimming 9,000 jobs from its 78,400 headcount.
During the company’s second quarter earnings call in August, executives said they are on track to deliver the targeted annualized savings of $1.3 billion by the end of 2026.
At Novo’s Sept. 21 capital markets day in London, CEO Mike Doustdar disclosed that staff departures have reached 13,000. The figure includes the initial 9,000 layoffs and 4,000 subsequent exits, according to Fierce Pharma. Novo’s headcount now stands at about 67,000.
Within New Jersey, Novo let go 263 workers in December 2025. It expects to lay off an additional 108 employees by the end of next month.
Novo’s portfolio includes popular GLP-1 treatments, such as type 2 diabetes drug Ozempic and weight management therapy Wegovy. However the company has struggled to maintain market share amid increased competition from rival Eli Lilly. Novo also faces the 2032 patent expiration of semaglutide, the key ingredient in Ozempic and Wegovy.
In an attempt to reassure investors, Novo recently pledged to launch at least five more blockbuster drugs by 2030 as well as deliver more than $23 billion in pipeline sales in 2035, according to Reuters.
The post GLP-1 drugmaker Novo plans 215 more job cuts in NJ appeared first on NJBIZ.

